Why DELFI Diagnostics’ New York approval could shake up the lung cancer screening market
DELFI Diagnostics can now offer FirstLook Lung in all 50 states. Find out what this means for blood-based cancer screening.
Can Caris Life Sciences turn Caris Assure into a broader precision oncology platform?
Caris wants New York access for Caris Assure. The bigger test is whether liquid biopsy scale can satisfy tougher state oversight.
Plus Therapeutics reimbursement push gains traction as AMA grants CNSide a dedicated PLA code
Plus Therapeutics has won an AMA PLA code for CNSide. Read why this reimbursement milestone could shape adoption, coverage, and diagnostic growth.